SCHEMBL8038

SCHEMBL8038

CC(=O)CN1CCNCC1

nearest known ligand 0.64

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CHRM5 P08912 2/20 0.55
CHRM3 P20309 2/20 0.55
SIGMAR1 Q99720 6/20 0.50
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
CA2 P00918 2/20 0.38
CA12 O43570 1/20 0.38
CA1 P00915 1/20 0.38
CA9 Q16790 1/20 0.38
CHKA P35790 1/20 0.37
POLB P06746 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
CHRNB2 P17787 1/20 0.35
CHRNA3 P32297 1/20 0.35
CHRNA4 P43681 1/20 0.35
CHRNB3 Q05901 1/20 0.35
CHRNA6 Q15825 1/20 0.35
HSD17B10 Q99714 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24247411 1.00 CHRM5 (0.55) CHRM5CHRM3SIGMAR1MEN1KMT2A
SCHEMBL13742551 0.98 CHRM5 (0.53) CHRM5CHRM3SIGMAR1MEN1KMT2A
Hydrochloric Acid SCHEMBL3925566 0.98 CHRM5 (0.53) CHRM5CHRM3SIGMAR1MEN1KMT2A
SCHEMBL12226505 0.92 CHRM5 (0.53) CHRM5CHRM3SIGMAR1MEN1KMT2A
SCHEMBL29299503 0.92 CHRM5 (0.49) CHRM5CHRM3SIGMAR1MEN1KMT2A
SCHEMBL29299504 0.90 CHRM5 (0.47) CHRM5CHRM3SIGMAR1MEN1KMT2A
SCHEMBL27404930 0.90 CHRM5 (0.47) CHRM5CHRM3SIGMAR1MEN1KMT2A
SCHEMBL13525120 0.90 CHRM5 (0.47) CHRM5CHRM3SIGMAR1MEN1KMT2A
SCHEMBL14728217 0.87 CHRM5 (0.45) CHRM5CHRM3SIGMAR1MEN1KMT2A
SCHEMBL16800789 0.85 SIGMAR1 (0.48) CHRM5CHRM3SIGMAR1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 201 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113604804-B Etching solution for stabilizing line width loss and etching cone angle in panel copper plating process 湖北兴福电子材料股份有限公司 2022-09-23 CN claimed
CN-113604804-A Etching solution for stabilizing line width loss and etching cone angle in panel copper plating process 湖北兴福电子材料有限公司 2021-11-05 CN claimed
US-20120301426-A1 ALKANOYLAMINO BENZAMIDE ANILINE HDAC INHIBITOR COMPOUNDS GILEAD SCIENCES, INC. (US) 2012-11-29 US claimed
EP-2440519-A1 ALKANOYLAMINO BENZAMIDE ANILINE HDAC INIHIBITOR COMPOUNDS Gilead Sciences, Inc. (US) 2012-04-18 EP claimed
WO-2010144371-A1 ALKANOYLAMINO BENZAMIDE ANILINE HDAC INIHIBITOR COMPOUNDS GILEAD COLORADO, INC. (US) 2010-12-16 WO claimed
US-20100310500-A1 ALKANOYLAMINO BENZAMIDE ANILINE HDAC INHIBITOR COMPOUNDS GILEAD SCIENCES, INC. (US) 2010-12-09 US claimed
EP-1789417-A1 AMIDE DERIVATIVES OF 7-AMINO-3-PHENYL-DIHYDROPYRIMIDO [4,5-d]PYRIMIDINONES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS F.HOFFMANN-LA ROCHE AG (CH) 2007-05-30 EP claimed
WO-2006024487-A1 AMIDE DERIVATIVES OF 7-AMINO-3-PHENYL-DIHYDROPYRIMIDO [4,5-d]PYRIMIDINONES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS F. HOFFMANN-LA ROCHE AG (CH) 2006-03-09 WO claimed
JP-61024572-A None JP disclosed
WO-2023250513-A1 13-MEMBERED MACROLIDE COMPOUNDS FOR TREATING DISEASES MEDIATED BY ABNORMAL PROTEIN TRANSLATION ZIKANI THERAPEUTICS, INC. (US) 2023-12-28 WO disclosed
US-20230357249-A1 ANDROGEN RECEPTOR PROTEIN DEGRADERS WITH A TRICYCLIC CEREBLON LIGAND UNIV MICHIGAN REGENTS (US) 2023-11-09 US disclosed
US-20230357307-A1 CLEAVABLE CYCLIC LOOP NUCLEOTIDES FOR NANOPORE SEQUENCING ILLUMINA, INC. 2023-11-09 US disclosed
EP-3740478-B1 FUSED IMIDAZOLE DERIVATIVES AS IL-17 MODULATORS UCB Biopharma SRL (BE) 2023-11-01 EP disclosed
WO-2023205625-A2 2,4 DNP AND PRODRUGS THEREOF FOR TREATMENT OF PULMONARY AND AUTOIMMUNE DISEASES MITOCHON PHARMACEUTICALS, INC. (US) 2023-10-26 WO disclosed
WO-2006038001-A1 AMINOPYRIMIDINE DERIVATIVES AS JNK INHIBITORS CELLTECH R & D LIMITED (GB) 2006-04-13 WO disclosed
WO-2006024487-A1 AMIDE DERIVATIVES OF 7-AMINO-3-PHENYL-DIHYDROPYRIMIDO [4,5-d]PYRIMIDINONES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS F. HOFFMANN-LA ROCHE AG (CH) 2006-03-09 WO disclosed
WO-2005014582-A1 QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS ASTRAZENECA AB (SE) 2005-02-17 WO disclosed
WO-1996034866-A1 IMIDAZO 1,2-A PYRIDINE AND IMIDAZO 1,2-A PYRIDEZINE DERIVATIVES AND THEIR USE AS BONE RESORPTION INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1996-11-07 WO disclosed
WO-1994000633-A1 METHODS OF DEINKING CELLULOSIC MATERIALS NEWPAPER ASSOCIATION OF AMERICA (US) 1994-01-06 WO disclosed
JP-S6124572-A NOVEL QUINOLINECARBOXYLIC ACID DERIVATIVE, ITS PREPARATION AND ANTIBACTERIAL AGENT CONTAINING SAID DERIVATIVE AS ACTIVE COMPONENT KANEBO LTD 1986-02-03 JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230357249-A1 ANDROGEN RECEPTOR PROTEIN DEGRADERS WITH A TRICYCLIC CEREBLON LIGAND AR, GPER1, CRBN CHRM5 1600/4885CHRM3 736/4885SIGMAR1 262/4885
US-20100310500-A1 ALKANOYLAMINO BENZAMIDE ANILINE HDAC INHIBITOR COMPOUNDS HDAC1, HDAC5, HDAC7 CHRM5 4813/4885CHRM3 4761/4885SIGMAR1 3981/4885
US-20120301426-A1 ALKANOYLAMINO BENZAMIDE ANILINE HDAC INHIBITOR COMPOUNDS HDAC1, HDAC5, HDAC7 CHRM5 4813/4885CHRM3 4761/4885SIGMAR1 3981/4885
US-20230357307-A1 CLEAVABLE CYCLIC LOOP NUCLEOTIDES FOR NANOPORE SEQUENCING TENT4A, TENT4B, DNTT CHRM5 4764/4885CHRM3 4505/4885SIGMAR1 4663/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.